DGS Capital Management LLC Reduces Stock Position in Novo Nordisk A/S (NYSE:NVO)

DGS Capital Management LLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 2.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,795 shares of the company’s stock after selling 1,208 shares during the quarter. Novo Nordisk A/S comprises 0.9% of DGS Capital Management LLC’s holdings, making the stock its 17th largest position. DGS Capital Management LLC’s holdings in Novo Nordisk A/S were worth $3,509,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Raymond James & Associates raised its holdings in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares during the period. Natixis Advisors LLC increased its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the last quarter. International Assets Investment Management LLC raised its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the period. LPL Financial LLC boosted its holdings in Novo Nordisk A/S by 3.6% in the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after purchasing an additional 47,496 shares during the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on NVO. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

Shares of NYSE:NVO opened at $87.94 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a 50 day simple moving average of $95.62 and a 200-day simple moving average of $115.55. The company has a market capitalization of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.